StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3028% below fair value
$17.83−0.49 (-2.67%)

Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –

Acadia Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Acadia Pharmaceuticals's pe ratio was 8.3× on Nov 11, 2026, against 16.2× a year earlier. Over the last 3 years it ranged from 3.9× to 92.1×, with a median of 11.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.3×−8.9
2025Dec 31, 202517.2×−6.3
2024Dec 31, 202423.5×+16.7
2012Jan 31, 20126.8×+1.9
2011Dec 30, 20114.9×–

More Acadia Pharmaceuticals figures

See a number that looks wrong?